Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Clinical experience with high-flow nasal cannula for COVID-19 patients in Japan

Takashi Katsuno, Manabu Suzuki, Masayuki Hojo, Jin Takasaki, Haruhito Sugiyama
European Respiratory Journal 2021 58: PA3772; DOI: 10.1183/13993003.congress-2021.PA3772
Takashi Katsuno
1Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: takatsuno@hosp.ncgm.go.jp
Manabu Suzuki
1Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masayuki Hojo
1Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jin Takasaki
1Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Haruhito Sugiyama
1Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

Introduction: We are amidst a coronavirus disease (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus-2. Oxygen administration is crucial in COVID-19 treatment, and high-flow nasal cannula (HFNC) prevents the need for intubation in patients with acute respiratory failure unlike conventional oxygen therapy. HFNC use for COVID-19 patients is limited owing to concerns of aerosol generation, therefore we aim to report our single-center experience with HFNC for COVID-19 patients.

Methods: A retrospective observational study on the use of HFNC for COVID-19 patients admitted to our institution from January 2020 to January 2021. 514 patients were included and divided into HFNC success or HFNC failure, depending on whether intubation could be avoided. Compared the basement characteristics and sequential change after HFNC therapy in both groups.

Results: Of 514 patients, 37 patients (7.2%) implemented HFNC due to deterioration. Of these, 24 patients (64.9%) were successfully managed, 4 (10.8%) were escalated to non-invasive ventilation, 7 (18.9%) were required intubation, 2 (5.4%) were palliated. The median duration of HFNC for HFNC success and HFNC failure patients was 5 days and 4 days, respectively. The median maximum FiO2 was 60 % and 100 %, respectively. In terms of sequential change of vital signs, SpO2/ FiO2 and heart rate improved in both groups, after 2–6 hours of HFNC use. All patients administered HFNC used a private negative pressure room. Nosocomial infections were not apparently reported during the study period.

Conclusions: The appropriate use of HFNC in COVID-19 patients is beneficial because it can reduce the aggravation and intubation rate.

  • Covid-19
  • Acute respiratory failure
  • Oxygen therapy

Footnotes

Cite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3772.

This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.

This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).

  • Copyright ©the authors 2021
Previous
Back to top
Vol 58 Issue suppl 65 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Clinical experience with high-flow nasal cannula for COVID-19 patients in Japan
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Clinical experience with high-flow nasal cannula for COVID-19 patients in Japan
Takashi Katsuno, Manabu Suzuki, Masayuki Hojo, Jin Takasaki, Haruhito Sugiyama
European Respiratory Journal Sep 2021, 58 (suppl 65) PA3772; DOI: 10.1183/13993003.congress-2021.PA3772

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Clinical experience with high-flow nasal cannula for COVID-19 patients in Japan
Takashi Katsuno, Manabu Suzuki, Masayuki Hojo, Jin Takasaki, Haruhito Sugiyama
European Respiratory Journal Sep 2021, 58 (suppl 65) PA3772; DOI: 10.1183/13993003.congress-2021.PA3772
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • MMP2 probe based on in vivo imaging technique for tracking ALI/ARDS in mice
  • Economic burden associated with clinical management of COVID-19 – A literature review
  • Late Breaking Abstract - Enhanced immune activation pathways enriched in patients =70 years with severe COVID-19
Show more Acute critical care

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society